Grufity logoGrufity logo

ATAI

3.09USD-0.08(-2.52%)Delayed

ATAI Life Sciences NV

Market Summary

USD3.09-0.08Delayed
-2.52%

ATAI Stock Price

RSI Chart

Valuation

Market Cap

485.5M

Price/Earnings

-2.51

Price/Sales

23.35

Price/Cashflow

-5.14

MarketCap/EBT

-3.52

Price/Sales

Profitability

EBT Margin

-676.19%

Return on Equity

-62.09%

Return on Assets

-55.46%

Fundamentals

Revenue

Revenue Y/Y

-99.65%

Revenue Q/Q

-81.1%

Earnings

Earnings (TTM)

-196.3M

Earnings Y/Y

-8.76%

Earnings Q/Q

7.46%

Price Action

52 Week Range

11.92
(Low)(High)

Last 7 days

0.7%

Last 30 days

3.5%

Last 90 days

-34.0%

Trailing 12 Months

-72.7%

Financial Health

Current Ratio

14.74

Investor Care

Shares Dilution (1Y)

3.48%

Diluted EPS (TTM)

-1.32

Financials for ATAI Life Sciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22021Q42021Q32021Q2
RevenueNaN%nullnull204060
Operating Expenses3.3%153148156198
  S&GA Expenses-12.3%8193139123
Earnings Before Taxes-4.8%-144.44-137.78-136.60-179.26
Net Income-1.4%-196.25-193.52-167.81-165.52
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.8%343349384414484
  Current Assets-1.9%317324349375442
    Cash Equivalents69.4%14384124362430
  Net PPE140.3%10000
Liabilities61.4%4729292821
  Current Liabilities18.0%2622222115
.    Short Term Borrowings-29.3%1622282110-
Shareholder's Equity-7.1%289312346377453
  Retained Earnings-7.9%-465.18-431.29-394.67-357.80-268.90
  Additional Paid-In Capital2.1%762746735725709
Shares Outstanding2.6%166162161161160
Minority Interest-20.9%788910
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations0.1%-94.47-94.54-70.71-63.25-48.95
  Share Based Compensation31.7%4433446386
Cashflow From Investing23.6%-215.53-282.20-292.29-81.28-36.51
Cashflow From Financing211.3%238379410490
  Buy Backs65.0%21211

Risks

What is the probability of a big loss on ATAI?

92.1%


Probability that ATAI Life Sciences stock will be more than 20% underwater in next one year

89.5%


Probability that ATAI Life Sciences stock will be more than 30% underwater in next one year.

71.0%


Probability that ATAI Life Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATAI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ATAI Life Sciences was unfortunately bought at previous high price.

Returns

Cumulative Returns on ATAI

Which funds bought or sold ATAI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
-
-
-732
4,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-27,000
343,000
-%
2022-11-17
M Holdings Securities, Inc.
ADDED
17.18
4,000
68,000
0.01%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-2,000
-
-%
2022-11-15
Verdence Capital Advisors LLC
UNCHANGED
-
-7,000
63,000
0.01%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
174
174
-%
2022-11-15
STATE STREET CORP
ADDED
102.9
162,000
354,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
84,000
84,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying ATAI calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ATAI

ATAI Life Sciences News

Marketscreener.com

IN BRIEF: Clarify Pharma invests in two "trailblazing" companies.3 days ago

Value the Markets

ATAI Fair Value

Recent SEC filings of ATAI Life Sciences

View All Filings
Date Filed Form Type Document
Nov 10, 2022
8-K
Current Report
Nov 10, 2022
8-K
Current Report
Nov 10, 2022
424B5
Prospectus Filed
Nov 10, 2022
10-Q
Quarterly Report
Nov 08, 2022
8-K
Current Report
Oct 14, 2022
8-K
Current Report
Sep 19, 2022
DEF 14A
DEF 14A
Sep 09, 2022
PRE 14A
PRE 14A

Latest Insider Trading transactions for ATAI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-04-29
Apeiron Investment Group Ltd.
BOUGHT
97,801
4.4658
21,900
-
2022-04-28
Apeiron Investment Group Ltd.
BOUGHT
154,689
4.4579
34,700
-
2022-04-27
Apeiron Investment Group Ltd.
BOUGHT
91,939.4
4.6427
19,803
-
2022-04-26
Apeiron Investment Group Ltd.
BOUGHT
216,628
4.6882
46,207
-
2022-04-25
Apeiron Investment Group Ltd.
BOUGHT
42,842.5
4.781
8,961
-
2022-04-22
Apeiron Investment Group Ltd.
BOUGHT
254,962
4.827
52,820
-
2022-04-21
Apeiron Investment Group Ltd.
BOUGHT
340,040
4.9505
68,688
-
2022-04-20
Apeiron Investment Group Ltd.
BOUGHT
344,514
5.0886
67,703
-
2022-04-19
Apeiron Investment Group Ltd.
BOUGHT
334,739
5.125
65,315
-
2022-04-18
Apeiron Investment Group Ltd.
BOUGHT
277,656
5.1113
54,322
-

1–10 of 24

Florian Brand
80
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATAI Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
License revenue$ 24$ 266$ 195$ 20,146
Operating expenses:    
Research and development19,02813,36352,43734,974
Acquisition of in-process research and development003578,934
General and administrative19,41920,26454,62366,868
Total operating expenses38,44733,627107,417110,776
Loss from operations(38,423)(33,361)(107,222)(90,630)
Other income (expense), net:    
Interest income145836180
Change in fair value of contingent consideration liability - related parties430469525(191)
Change in fair value of derivative liability00041
Change in fair value of warrant liability0475387
Change in fair value of securities carried at fair value3440(981)0
Unrealized loss on other investments held at fair value0(70)0(5,530)
Loss on conversion of convertible promissory notes000(513)
Gain on consolidation of a variable interest entity0003,543
Foreign exchange gain (loss), net4,4706,46211,5155,446
Other income (expense), net(100)(29)(112)(355)
Total other income (expense), net5,2896,88711,3612,608
Loss before income taxes(33,134)(26,474)(95,861)(88,022)
Provision for income taxes(135)(368)(227)(432)
Gain on dilution of equity method investment00016,923
Losses from investments in equity method investees, net of tax(2,432)(4,800)(14,680)(9,440)
Net loss(35,701)(31,642)(110,768)(80,971)
Net loss attributable to redeemable noncontrolling interests and noncontrolling interests(1,814)(484)(3,394)(2,040)
Net loss attributable to ATAI Life Sciences N.V. stockholders$ (33,887)$ (31,158)$ (107,374)$ (78,931)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - basic$ (0.22)$ (0.21)$ (0.69)$ (0.59)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - diluted$ (0.22)$ (0.21)$ (0.69)$ (0.59)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic156,607,468151,130,212154,713,922134,334,685
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders - diluted156,607,468151,130,212154,713,922134,334,685

ATAI Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 142,539$ 362,266
Securities carried at fair value161,5180
Prepaid expenses and other current assets13,42511,903
Short term notes receivable0913
Total current assets317,482375,082
Property and equipment, net728149
Equity Method Investments016,131
Other investments8,49811,628
Long term notes receivable - related parties7,1513,835
Other assets8,7387,341
Total assets342,597414,166
Current liabilities:  
Accounts payable3,5116,004
Accrued liabilities22,14214,829
Current portion of contingent consideration liability - related parties051
Other current liabilities26051
Total current liabilities25,91320,935
Non-current portion of contingent consideration liability - related parties1,9082,432
Convertible promissory notes - related parties, net of discounts and deferred issuance costs380743
Other liabilities3,6954,097
Long-term debt, net14,6210
Total liabilities46,51728,207
Commitments and contingencies (Note 15)
Stockholders' equity:  
Common stock, $0.10 par value ($0.12 par value at September 30, 2022 and December 31, 2021, respectively); 750,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; 165,875,307 and 160,677,001 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively18,55418,002
Additional paid-in capital761,811725,045
Accumulated other comprehensive loss(25,788)(8,336)
Accumulated deficit(465,178)(357,803)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders289,399376,908
Noncontrolling interests6,6819,051
Total stockholders' equity296,080385,959
Total liabilities and stockholders' equity$ 342,597$ 414,166